The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cohort-level patient-derived organoid assays and prediction of clinical trial outcomes in PDAC.
 
Gustave Ronteix
Employment - Orakl Oncology
Leadership - Orakl Oncology
Stock and Other Ownership Interests - Orakl Oncology
 
Jean Bouteiller
Employment - Orakl Oncology
Stock and Other Ownership Interests - Orakl Oncology
 
Anna-Rose Gryspeert
Employment - Orakl Oncology
 
Alice Boileve
Travel, Accommodations, Expenses - Ipsen (Inst); SERVIER (Inst)
 
Cartry Jerome
Stock and Other Ownership Interests - Orakl Oncology
 
Jacques Mathieu
No Relationships to Disclose
 
Sabrina Bedja
No Relationships to Disclose
 
Michel Ducreux
Employment - Sandoz (I)
Honoraria - Bayer; Pierre Fabre; Roche/Genentech; TERUMO
Consulting or Advisory Role - Abbvie (Inst); Abcely; Amgen; Astellas Pharma; AstraZeneca; Basilea; Bayer; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; HalioDx; Ipsen; Lilly; Merck Serono; MSD; Novartis; Pierre Fabre; Rafael Pharmaceuticals; Roche; Scandion Oncology; Servier; Sotio; Zymeworks
Speakers' Bureau - Amgen; AstraZeneca; Bayer; GlaxoSmithKline; HalioDx; Lilly; Merck KGaA; MSD; Pierre Fabre; Roche; SERVIER
Research Funding - Keocyt (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Merck Serono; Pierre Fabre; Roche; SERVIER
 
Fanny Jaulin
Employment - Orakl Oncology
Leadership - Orakl Oncology
Stock and Other Ownership Interests - Orakl Oncology
Research Funding - AstraZeneca (Inst)